

The industry perspective

Carlo Incerti

Head of Global Medical Affairs, Genzyme
Member of the IMI Governing Board

How IMI accelerates access to affordable medicines?

Multiple companies join force where they would fail alone:

Identify missing or weak links in medicines pathways that hold progress

Combine (often) proprietary knowledge, data and assets

Open them up for challenge by and **collaboration with public partners**

Validate proposed solutions during project lifetime in R&D practice



Solutions for diseases with high burden and cost for patients and society



Solutions that challenge current business models and focus on value for patients and sustainable healthcare



Tracking and addressing science gaps and inefficiencies from discovery to disease management

IMI vs. 2013 WHO report on priority diseases for Europe and the world

WHO report for Europe and the World (in green areas addressed by IMI - see the following columns)	IMI2 SRA	Already addressed (*directly or *indirectly through tools, infrastructures and methodologies)		IMI2 Planned
		IMI1	IMI2	
AMR	Yes	**	**	**
Pandemic and seasonal influenza	Yes	**	**	**
Ischemic heart disease	Yes	*	*	**
Diabetes	Yes	**	**	**
Cancer	Yes	**	**	**
Acute stroke	Yes	*	*	*
HIV/AIDS		*	*	*
Tuberculosis	Yes	**	*	*
Depression	Yes	**	**	*
Neglected tropical diseases		*	*	*
Alzheimer and other dementias	Yes	**	**	**
COPD	Yes	**	*	**
Alcohol use disorders				
Post partum Hemorrhage				
Tobacco use				
Obesity	Yes	**	*	*
Rare diseases	Yes	*	*	*
Diarrhea				
Hearing loss				
Pneumonia				
Neonatal conditions			*	
Low back pain		*	*	**
Medicines for children			**	**
Medicines for women			*	*
Medicines for elderly	Yes	**	*	**
Personalized medicine	Yes	**	**	**



Solutions for diseases with high burden for patients and society (prevention, diagnosis, treatment and management)

Diabetes

From tools for research, to understanding the disease and early detection of complications



Alzheimer's disease

From discovery to delivery, from prevention to treatment and disease



Rheumatoid arthritis

Understanding the disease, addressing risks of biological products and managing chronic pain



Antimicrobial resistance

Rapid diagnostics, understand resistance, progress and fill in research pipelines, set up specialised clinical trials networks





Solutions that challenge current business models and focus on value for patients and sustainable healthcare

Outcomes research

Define and measure outcomes that are meaningful for patient and society and generate missing data from real world use of healthcare products

BD4BO

Leukemias
Cardiovascular
Diseases
Alzheimer's
Disease

Patient centricity

Meaningful patient involvement in medicines pathways (R&D, evaluation, delivery) will deliver better data and information and make results of research more relevant for healthcare systems



Real world evidence

Digital and IT tools help generating high quality data which inform healthcare systems on real impact of medicines in real use conditions



BD4BO

Driving reinvestment

Balancing rational use of antibiotics, cost for healthcare systems and return on investment





Holistic approach to track and address science gaps and inefficiencies from discovery to disease management

Safety and Efficacy

Unprecedented level of data and knowledge sharing delivers new tools and knowledge on safety and efficacy of medicines and vaccines.



Big data solutions

Combining data from different companies and sources to find new biomarkers or targets (new treatment pathways) and making better: Projects deliver data infrastructures, tools for collecting, mining and interpreting new sources of evidence



New trials design

More collaborative approaches, better tools to identify and enrol the right patients and the right number of patients makes trials more effective and better for healthcare systems and for individual patients.



A few examples – recent success stories

- **Ebola+** – 3 months from idea to project start – inspired current response to Zika
- **EU-Aims** – methodology for stratification of patients with ASD supported by EMA
- **Quic-Concept** – biomarker driven trials in Oncology – consensus framework agreed with regulatory bodies, pharmaceutical companies, and patients
- **Big Data for Better Outcomes** – involvement of public health systems players to drive new business models based on outcomes